|
Gene: NWD1 |
Gene summary for NWD1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NWD1 | Gene ID | 284434 |
Gene name | NACHT and WD repeat domain containing 1 | |
Gene Alias | NWD1 | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q149M9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284434 | NWD1 | HCC1 | Human | Liver | HCC | 7.03e-21 | 2.11e+00 | 0.5336 |
284434 | NWD1 | HCC2 | Human | Liver | HCC | 2.75e-38 | 2.24e+00 | 0.5341 |
284434 | NWD1 | HCC5 | Human | Liver | HCC | 4.48e-36 | 2.11e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NWD1 | SNV | Missense_Mutation | rs145011343 | c.2165C>T | p.Thr722Met | p.T722M | Q149M9 | protein_coding | deleterious(0.04) | benign(0.009) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NWD1 | SNV | Missense_Mutation | rs770074174 | c.3092C>T | p.Thr1031Met | p.T1031M | Q149M9 | protein_coding | tolerated(0.05) | benign(0.272) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
NWD1 | SNV | Missense_Mutation | c.4250N>C | p.Leu1417Pro | p.L1417P | Q149M9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A1AQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
NWD1 | SNV | Missense_Mutation | c.2251N>C | p.Gly751Arg | p.G751R | Q149M9 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
NWD1 | SNV | Missense_Mutation | rs141165642 | c.3964N>A | p.Val1322Ile | p.V1322I | Q149M9 | protein_coding | tolerated(0.22) | benign(0.043) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NWD1 | SNV | Missense_Mutation | c.772N>G | p.His258Asp | p.H258D | Q149M9 | protein_coding | deleterious(0.01) | possibly_damaging(0.871) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NWD1 | SNV | Missense_Mutation | rs548514304 | c.3341N>T | p.Ser1114Leu | p.S1114L | Q149M9 | protein_coding | tolerated(0.09) | benign(0.155) | TCGA-E9-A54X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NWD1 | SNV | Missense_Mutation | novel | c.4203N>C | p.Gln1401His | p.Q1401H | Q149M9 | protein_coding | deleterious(0.02) | possibly_damaging(0.871) | TCGA-HN-A2NL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
NWD1 | SNV | Missense_Mutation | novel | c.1638G>T | p.Trp546Cys | p.W546C | Q149M9 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-LL-A5YP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
NWD1 | SNV | Missense_Mutation | c.3136N>C | p.Glu1046Gln | p.E1046Q | Q149M9 | protein_coding | tolerated(0.08) | possibly_damaging(0.628) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |